Facts and figures

products icon

29.2 million patients use our diabetes products

products icon

Our products are marketed in 170 countries

affiliates icon

We have affiliates in 80 countries

Our products

Main product areas

Growth disorders
Hormone replacement therapy

Our products



Annual sales

111,831 million Danish kroner 

Total sales
9 months 2019

89,604 million Danish kroner

Third-quarter results for 2019


Sales by region
9 months 2019

North America Operations

43,391 million Danish kroner

USA: 41,234 million Danish kroner

Canada: 2,157 million Danish kroner


International Operations

46,213 million Danish kroner

Region Europe: 17,105 million Danish kroner

Region AAMEO: 10,810 million Danish kroner

Region China: 9,825 million Danish kroner

Region Japan & Korea: 4,719 million Danish kroner

Region Latin America: 3,754 million Danish kroner


Sales by business segment
9 months 2019

Diabetes and obesity care total

75,510 million Danish kroner


Biopharmaceuticals total

14,094 million Danish kroner



research icon

We invest 13.2% of sales in R&D

employee icon

19% of our global workforce works within R&D

research icon

We have R&D centres in China, Denmark, India, UK and US

Our research focus


All people diagnosed with diabetes should receive treatment

Learn more about our access and affordability activities

Graphic: Insulin vials

In 2018, 5 million people with diabetes were treated with our human insulin at a maximum of 4 USD per 10ml vial

Graphic: Children

Our Changing Diabetes in Children® programme has provided treatment to 19,000+ children with type 1 diabetes

Graphic: Donations

In 2018, we donated 85 million Danish kroner to the World Diabetes Foundation


Number of employees

More than 42,200 employees (FTEs as of September 2019)

Business area distribution

19% within research and development

33% in production and production administration

39% in international sales and marketing

9% in administration

Novo Nordisk employees angaging

Affiliate distribution (FTEs as of September 2019)

Approximately 39% of employees are located in Denmark (16,360 FTEs) and 61% in the rest of the world:

Africa, Asia, Middle East & Oceania: 7,482

China & Taiwan: 4,885

Denmark: 16,360

Europe (excl. HQ): 4,175

Japan (993) & Korea: 1,147

Latin America: 2,005

North America (US 5,785 & Canada 319): 6,104

(includes Novo Nordisk and NNE employees)



affiliates icon

We supply nearly half the world's insulin


Clean energy icon

By 2020 all our production will run on 100% renewable power

research icon

We have production sites in Brazil, China, Denmark, France and the US


We are located in Denmark

Novo Nordisk A/S
Novo Allé 1
2880 Bagsværd
CVR nr. 24 25 67 90

Contact us